United States securities and exchange commission logo

                           April 19, 2022

       Edward Smith
       Chief Financial Officer
       LAVA Therapeutics NV
       Yalelaan 60
       3584 CM Utrecht
       The Netherlands

                                                        Re: LAVA Therapeutics
Statement on Form F-3
                                                            Filed April 12,
                                                            File No. 333-264246

       Dear Mr. Smith:

              This is to advise you that we have not reviewed and will not
review your registration

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Dorrie
Yale at 202-551-8776 with any questions.


                           Division of Corporation Finance

                           Office of Life Sciences
       cc:                                              Peter Jaslow